Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$3.25
-0.10 (-2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-12.5M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$39M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-350.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-46.9M · FCF $-12.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | $12000.00 | — | — | $1.4M |
| Net Income | $-46.9M | $-46.9M | $-18.5M | $-48.8M | $-10.3M | $-8.5M |
| EBITDA | $-23.5M | $-23.5M | $-18.3M | $-13.6M | $-10.2M | $-8.6M |
| EPS | -40.50 | -40.50 | -34.50 | -1.03 | -1.03 | — |
| Gross Margin | — | — | — | — | — | 51.9% |
| Operating Margin | — | — | -155058.3% | — | — | -601.3% |
| Net Margin | — | — | -153825.0% | — | — | -599.3% |
| Balance Sheet | ||||||
| Debt/Equity | — | — | 0.03 | 0.03 | — | — |
| Current Ratio | — | — | 41.56 | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-12.5M | $-12.5M | $-16.1M | $-11.1M | $-8.8M | $-5.2M |
| Returns | ||||||
| ROE | -350.2% | -350.2% | -164.6% | -234.4% | -41.6% | -132.6% |
| Valuation | ||||||
| P/B | — | — | 0.16 | 141.69 | 179.34 | — |
| Growth & Yield | ||||||
| EPS Growth | -17.4% | -17.4% | -3241.0% | -0.1% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-48.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-34.50 → -40.50
Residual
-48.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.